While bispecific antibodies target two specific entities, multispecific antibodies can target more than two. The use of these engineered antibodies offers the potential for enhanced therapeutic strategies by simultaneously addressing multiple aspects of a disease.

Advancements in cytokine understanding and synthetic immunology enable precise immune modulation, particularly in cancer treatment. However, challenges like short half-lives and side effects impact their wider clinical application.

Discussing using a computational drug discovery platform for the development of multispecific antibody therapeutics.

This whitepaper by Sino Biological discusses the different types of stem cells based on their origin and potential, as well as the factors that direct their differentiation toward specific lineages or cell types.

The company can now sell their biologic for ulcerative colitis in a subcutaneous form on the US market.

F-star Therapeutics and Takeda are partnering to develop next-generation multi-specific antibodies for cancer immunotherapy, building on F-star's advanced platforms.

Amgen and Synaffix's partnership aims to revolutionise cancer treatment by developing highly targeted antibody-drug conjugates (ADCs).

On-Demand Workshop presented by Andreas Castan, Strategic Technologies Director at Cytiva, Cauroline Hausner, Business Development Manager, Aseptic Filling at Cytiva, Ola Tuvesson, Chief Technology Officer at NorthX Biologics & Sofie Östemar, Product Manager, Connected & Continuous at Cytiva

Xentria and Meitheal partner to develop a breakthrough drug for pulmonary sarcoidosis, aiming to improve patient outcomes.

We take a look at the work of Sir Gregory Winter, and how it has changed the landscape of therapeutic antibody production.